US › Healthcare

Oncolytics Biotech Inc (ONCY)

US · Healthcare · Biotechnology

$0.50-9.09%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-9.4M

EPS

$-0.08

EPS estimate

$-0.07

EPS came in at -0.08 against a street estimate of -0.07 — a miss of 14.3%.

Key statistics

Market cap

$73.0M

Forward P/E

45.5

P/B

1,055.04

Book value

$-0.05

EPS (TTM)

$-0.35

52-week high

$1.32

52-week low

$0.53

50-day MA

$0.76

200-day MA

$0.90

Beta

1.16

Analyst view

Analysts rate Oncolytics Biotech Inc a buy (5 buy, 1 hold, 0 sell out of 6) with an average price target of $4.14.

Shareholding

Insiders

1.66%

Institutions

9.05%

Largest institutional holders

Fund	Stake
Marshall Wace Asset Management Ltd	0.58%
Sandbox Financial Partners, LLC	0.31%
XTX Topco Ltd	0.20%
SEEDS INVESTOR LLC	0.20%
International Assets Investment Management, LLC	0.16%
Connective Capital Management LLC	0.15%
Goldman Sachs Asset Management, L.P.	0.13%
Tocqueville Asset Management L.P.	0.12%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Oncolytics Biotech Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.